Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma

Cancer Genetics

Volumn 205, Issue 7-8, 2012, Pages 391-404

  Jahromi, Mona S ^a   Putnam, Angelica R ^b   Druzgal, Colleen ^c   Wright, Jennifer ^a,b   Spraker Perlman, Holly ^a,b   Kinsey, Michelle ^a,b   Zhou, Holly ^b   Boucher, Kenneth M ^b   Randall, R Lor ^a,b   Jones, Kevin B ^a,b   Lucas, David ^d   Rosenberg, Andrew ^e   Thomas, Dafydd ^d   Lessnick, Stephen L ^a,b   Schiffman, Joshua D ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CEBPB; Copy number; Ewing sarcoma; Outcome; SMARCB1 INI1 SNF5

Indexed keywords

REELIN; SMARCB1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NERVE CELL ADHESION MOLECULE; NERVE PROTEIN; NONHISTONE PROTEIN; PARAFFIN; REELIN PROTEIN; SCLEROPROTEIN; SERINE PROTEINASE; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CEBPB GENE; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER ALTERATION; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; METASTASIS; MOLECULAR INVERSION PROBE; MOLECULAR PATHOLOGY; MOLECULAR PROBE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REELIN GENE; SCHOOL CHILD; SMARCB1 GENE; TISSUE MICROARRAY; BONE TUMOR; GENE DOSAGE; GENETICS; INFANT; PATHOLOGY;

ADOLESCENT; ADULT; BONE NEOPLASMS; CELL ADHESION MOLECULES, NEURONAL; CHILD; CHILD, PRESCHOOL; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE DELETION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LOSS OF HETEROZYGOSITY; MALE; MOLECULAR PROBES; NERVE TISSUE PROTEINS; PARAFFIN EMBEDDING; SARCOMA, EWING; SERINE ENDOPEPTIDASES; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84867145989     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.05.012     Document Type: Article

References (66)

1. Carvajal R., Meyers P. Ewing's sarcoma and primitive neuroectodermal family of tumors. Hematol Oncol Clin North Am 2005, 19:501-525. vi-vii.
2. Esiashvili N., Goodman M., Marcus R.B. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol 2008, 30:425-430.
3. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000 2006, National Cancer Institute, Bethesda, MD, NIH Pub. No. 06-5767. A. Bleyer, M. O'Leary, R. Barr (Eds.).
4. Jawad M.U., Cheung M.C., Min E.S., et al. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer 2009, 115:3526-3536.
5. Linabery A.M., Ross J.A. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer 2008, 113:2575-2596.
6. Grier H.E., Krailo M.D., Tarbell N.J., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003, 348:694-701.
7. DuBois S.G., Krailo M.D., Lessnick S.L., et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009, 52:324-327.
8. Turc-Carel C., Aurias A., Mugneret F., et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988, 32:229-238.
9. Toomey E.C., Schiffman J.D., Lessnick S.L. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 2010, 29:4504-4516.
10. Huang H.Y., Illei P.B., Zhao Z., et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005, 23:548-558.
11. Armengol G., Tarkkanen M., Virolainen M., et al. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 1997, 75:1403-1409.
12. Ozaki T., Paulussen M., Poremba C., et al. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 2001, 32:164-171.
13. Hattinger C.M., Potschger U., Tarkkanen M., et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 2002, 86:1763-1769.
14. Maurici D., Perez-Atayde A., Grier H.E., et al. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet Cytogenet 1998, 100:106-110.
15. Wei G., Antonescu C.R., de Alava E., et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 2000, 89:793-799.
16. Tarkkanen M., Kiuru-Kuhlefelt S., Blomqvist C., et al. Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet Cytogenet 1999, 114:35-41.
17. Jahromi M.S., Jones K.B., Schiffman J.D. Copy number alterations and methylation in Ewing's sarcoma. Sarcoma 2011, 2011:362173.
18. Savola S., Klami A., Tripathi A., et al. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009, 9:17.
19. Shing D.C., Morley-Jacob C.A., Roberts I., et al. Ewing's tumour: novel recurrent chromosomal abnormalities demonstrated by molecular cytogenetic analysis of seven cell lines and one primary culture. Cytogenet Genome Res 2002, 97:20-27.
20. Ferreira B.I., Alonso J., Carrillo J., et al. Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene 2008, 27:2084-2090.
21. Zielenska M., Zhang Z.M., Ng K., et al. Acquisition of secondary structural chromosomal changes in pediatric Ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer 2001, 91:2156-2164.
22. Jahromi M.S., Jones K.B., Schiffman J.S. Copy number alterations (CNAs) and methylation in Ewing's sarcoma. Sarcoma 2011, 2011:362173.
23. Wang Y., Carlton V.E., Karlin-Neumann G., et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2009, 2:8.
24. Wang Y., Moorhead M., Karlin-Neumann G., et al. Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol 2007, 8:R246.
25. Brewster A.M., Thompson P., Sahin A.A., et al. Copy number imbalances between screen and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res (Phila) 2011, 4:1609-1616.
26. Schiffman J.D., Lorimer P.D., Rodic V., et al. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol 2011, 155:477-486.
27. Wang Y., Moorhead M., Karlin-Neumann G., et al. Allele quantification using molecular inversion probes (MIP). Nucleic Acids Res 2005, 33:e183.
28. Schiffman J.D., Hodgson J.G., VandenBerg S.R., et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010, 70:512-519.
29. Schiffman J.D., Wang Y., McPherson L.A., et al. Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. Cancer Genet Cytogenet 2009, 193:9-18.
30. Ji H., Welch K. Molecular inversion probe assay for allelic quantitation. Methods Mol Biol 2009, 556:67-87.
31. Wang Y., Cottman M., Schiffman J.D. Molecular inversion probes: a novel microarray technology and its application in cancer research. Cancer Genet 2012, 205:341-355. [in this issue].
32. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 1995, 57:289-300.
33. Hollmann T.J., Hornick J.L. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol 2011, 35:e47-e63.
34. Houglum K., Buck M., Adir V., et al. LAP (NF-IL6) transactivates the collagen alpha 1(I) gene from a 5' regulatory region. J Clin Invest 1994, 94:808-814.
35. Tsuchimochi K., Otero M., Dragomir C.L., et al. GADD45beta enhances Col10a1 transcription via the MTK1/MKK3/6/p38 axis and activation of C/EBPbeta-TAD4 in terminally differentiating chondrocytes. J Biol Chem 2010, 285:8395-8407.
36. Ng P.K., Tsui S.K., Lau C.P., et al. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem 2010, 110:438-446.
37. Sollazzo M.R., Benassi M.S., Magagnoli G., et al. Increased c-myc oncogene expression in Ewing's sarcoma: correlation with Ki67 proliferation index. Tumori 1999, 85:167-173.
38. Neale G., Su X., Morton C.L., et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008, 14:4572-4583.
39. Okamura Y., Nomoto S., Kanda M., et al. Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol 2011, 18:572-579.
40. Sato N., Fukushima N., Chang R., et al. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 2006, 130:548-565.
41. Resende C., Ristimäki A., Machado J.C. Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter 2010, 15(Suppl. 1):34-39.
42. Dohi O., Takada H., Wakabayashi N., et al. Epigenetic silencing of RELN in gastric cancer. Int J Oncol 2010, 36:85-92.
43. Karlsson E., Waltersson M.A., Bostner J., et al. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 2011, 50:775-787.
44. Gorringe K.L., George J., Anglesio M.S., et al. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One 2010, 5:e11408.
45. Weir B.A., Woo M.S., Getz G., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
46. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
47. Caren H., Kryh H., Nethander M., et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A 2010, 107:4323-4328.
48. George R.E., Attiyeh E.F., Li S., et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2007, 2:e255.
49. Forshew T., Tatevossian R.G., Lawson A.R., et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009, 218:172-181.
50. Paulsson K., Cazier J.B., Macdougall F., et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A 2008, 105:6708-6713.
51. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
52. Mullighan C.G., Su X., Zhang J., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360:470-480.
53. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009, 106:9414-9418.
54. Eaton K.W., Tooke L.S., Wainwright L.M., et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2011, 56:7-15.
55. Hoot A.C., Russo P., Judkins A.R., et al. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol 2004, 28:1485-1491.
56. Kohashi K., Oda Y., Yamamoto H., et al. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol 2008, 32:1168-1174.
57. Mobley B.C., McKenney J.K., Bangs C.D., et al. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol 2010, 120:745-753.
58. Hornick J.L., Dal Cin P., Fletcher C.D. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 2009, 33:542-550.
59. Modena P., Lualdi E., Facchinetti F., et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 2005, 65:4012-4019.
60. Cheng J.X., Tretiakova M., Gong C., et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol 2008, 21:647-652.
61. Kreiger P.A., Judkins A.R., Russo P.A., et al. Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas. Mod Pathol 2009, 22:142-150.
62. Trobaugh-Lotrario A.D., Tomlinson G.E., Finegold M.J., et al. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009, 52:328-334.
63. Sumegi J., Nishio J., Nelson M., et al. A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor. Mod Pathol 2011, 24:333-342.
64. Franco S.J., Martinez-Garay I., Gil-Sanz C., et al. Reelin regulates cadherin function via Dab1/Rap1 to control neuronal migration and lamination in the neocortex. Neuron 2011, 69:482-497.
65. Nichols A.J., Olson E.C. Reelin promotes neuronal orientation and dendritogenesis during preplate splitting. Cereb Cortex 2010, 20:2213-2223.
66. Stein T., Cosimo E., Yu X., et al. Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol 2010, 177:2323-2333.